BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma
Wenbo Qi
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
*With equal contribution.
Search for more papers by this authorYuping Bai
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
*With equal contribution.
Search for more papers by this authorYiran Wang
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Search for more papers by this authorLe Liu
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Search for more papers by this authorYaqing Zhang
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Search for more papers by this authorYang Yu
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Search for more papers by this authorCorresponding Author
Hao Chen
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Hao Chen, Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China. e-mail: [email protected]
Search for more papers by this authorWenbo Qi
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
*With equal contribution.
Search for more papers by this authorYuping Bai
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
*With equal contribution.
Search for more papers by this authorYiran Wang
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Search for more papers by this authorLe Liu
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Search for more papers by this authorYaqing Zhang
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Search for more papers by this authorYang Yu
The Second Clinical Medical College of Lanzhou University, Lanzhou, China
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Search for more papers by this authorCorresponding Author
Hao Chen
Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou, China
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
Hao Chen, Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China. e-mail: [email protected]
Search for more papers by this authorAbstract
Accurate assessment of the tumour immune microenvironment promotes individualized immunotherapy regimens and screens dominant populations suitable for immunotherapy. Therefore, potential molecular markers were investigated to make an overall assessment of the immune microenvironment status of liver hepatocellular carcinoma (LIHC). In this study, a total of 121 differentially expressed genes (DEGs) were identified, and DEGs were enriched in the epithelial–mesenchymal transition, hypoxia, myogenesis, and p53 pathways. A total of 20 hub genes were selected and a strong correlation was identified between these hub genes and prognosis. The expression of budding uninhibited by benzimidazoles 1 (BUB1) was found to be upregulated in LIHC and was strongly related to immune cells and immune checkpoint molecule expression. Immunohistochemistry (IHC) indicated that BUB1 expression was higher in LIHC tissues than in normal liver tissues. BUB1 knockdown resulted in reduced proliferation and vertical migration ability of LIHC cells, and reduced the expression of phospho-SMAD family member 2 and phospho-SMAD family member 3 proteins. IHC showed that BUB1 expression was accompanied by immune cell infiltration into LIHC tissues. These results suggest that BUB1 may serve as a potential prognostic biomarker for LIHC and as an indicator of its immune status.
Conflict of interest
The authors have no conflicts of interest to declare.
References
- 1Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.
- 2Siegel R, Miller K, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30.
- 3Torrecilla S, Llovet J. New molecular therapies for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2015; 39: 80–6.
- 4Lou W, Liu J, Gao Y, Zhong G, Ding B, Xu L, et al. MicroRNA regulation of liver cancer stem cells. Am J Cancer Res. 2018; 8: 1126–41.
- 5Shlomai A, Jong Y, Rice C. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014; 26: 78–88.
- 6Hato T, Goya L, Greten T, Duda D, Zhu A. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014; 60: 1776–82.
- 7Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the antitumour immune responses. J Viral Hepat. 2010; 17: 34–43.
- 8Yu H, Tang Z. Bub1 multitasking in mitosis. Cell Cycle. 2005; 4: 262–5.
- 9Kang J, Yang M, Li B, Qi W, Zhang C, Shokat KM, et al. Structure and substrate recruitment of the human spindle checkpoint kinase Bub1. Mol Cell. 2008; 32: 394–405.
- 10Stahl D, Braun M, Gentles AJ, Lingohr P, Walter A, Kristiansen G, et al. Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma. Oncotarget. 2017; 8: 76329–39.
- 11Morris B, Willcox D, Donlon T, Willcox B. FOXO3: a major gene for human longevity–a mini-review. Gerontology. 2015; 61: 515–25.
- 12Zhang L, Huang YI, Ling J, Zhuo W, Yu Z, Shao M, et al. Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches. Cancer Biomark. 2018; 22: 511–21.
- 13Gautier L, Cope L, Bolstad B, Irizarry R. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20: 307–15.
- 14Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43: e47–59.
- 15Yu G, Wang L, Han Y, He Q. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16: 284–7.
- 16Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015; 43: D447–52.
- 17Smoot E, Ono K, Ruscheinski J, Wang P, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011; 27: 431–2.
- 18Chin C, Chen S, Wu H, Ho C, Ko M, Lin C. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014; 8: S11–6.
- 19Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45: W98–W102.
- 20Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017; 77: e108–18.
- 21Nyati S, Schinske-Sebolt K, Pitchiaya S, Chekhovskiy K, Chator A, Chaudhry N, et al. The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling. Sci Signal. 2015; 8: 358.
- 22Nyati S, Gregg BS, Xu J, Young G, Kimmel L, Nyati MK, et al. TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-b signaling. Neoplasia. 2020; 22: 163–78.
- 23Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38: 396–417.
- 24Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017; 16: 149–58.
- 25Floudas CS, Brar G, Greten TF. Immunotherapy: current status and future perspectives. Dig Dis Sci. 2019; 64: 1030–40.
- 26Han J, Han Y, Park G, Kim S, Lee C. Bub1 is required for maintaining cancer stem cells in breast cancer cell lines. Sci Rep. 2015; 5: 15993–6000.
- 27Lin TH, Shao YY, Chan SY, Huang CY, Hsu CH, Cheng AL, et al. High serum transforming growth factor-beta1 levels predict outcome in hepatocellular carcinoma patients treated with Sorafenib. Clin Cancer Res. 2015; 21: 3678–84.
- 28Li M, Flavell R. TGF-β: a master of all T cell trades. Cell. 2008; 134: 392–404.
- 29Chen W, Dijke P. Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol. 2016; 16: 723–40.
- 30Achyut B, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology. 2011; 141: 1167–78.
- 31Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554: 544–548.
- 32Moustakas A. The mitotic checkpoint protein kinase BUB1 is reported as an engine in the TGF-β signaling apparatus. Sci Signal. 2015; 8: 359.
- 33Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, et al. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019; 7: 27–40.
